Imovane 7.5mg

Novo-Imovane 7.5mg is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to Imovane 7.5mg's benzodiazepine pharmacological properties it also has some barbiturate like properties.

In the treatment of transient, situational and chronic insomnia.

In the case of situational transient insomnia, such as in shift workers, short-term treatment (3-7 days) with Imovane 7.5mg at the recommended dosage will be sufficient to re-establish normal sleep.

In insomnia secondary to psychiatric disorders including difficulty in falling asleep, nocturnal awakenings, and early wakening.

Insomnia caused by more persisting life stress or psychological distress can demand longer treatment with Imovane 7.5mg than for situational - transient insomnia. However patients need to be periodically assessed for their insomnia and treatment should not be prolonged if not necessary.

Zopiclonebelongs to the group of medicines called central nervous system (CNS) depressants (medicines that make you drowsy or less alert). Imovane 7.5mg is used to treat insomnia (trouble in sleeping). Imovane 7.5mg helps you get to sleep faster and sleep through the night. In general, when sleep medicines are used every night for a long time, they may lose their effectiveness. In most cases, sleep medicines should be used only for short periods of time, such as 1 or 2 days, and generally for no longer than 1 or 2 weeks.

Imovane 7.5mg is available only with your doctor's prescription.

The average therapeutic dose of Imovane 7.5mg Synthon Pharmaceuticals is 7.5 mg orally at night, in cases of severe insomnia the dose can be increased up to 15 mg. In elderly patients, as well as abnormal liver function is used 3.75 mg.

Imovane 7.5mg causes impaired driving skills which are similar to benzodiazepines. Long term users of hypnotic drugs for sleep disorders only develop partial tolerance to adverse effects on driving with users of hypnotic drugs even after 1 years use still showing an increased motor vehicle accident rate. Patients who drive motor vehicles should not take Imovane 7.5mg unless they stop driving due to a significant increased risk of road traffic accidents in Imovane 7.5mg users. Imovane 7.5mg induces impairment of psychomotor function. Driving or operating machinery should be avoided after taking Imovane 7.5mg as effects can carry over to the next day including impaired hand eye coordination. Patients with a history of substance abuse should not be prescribed Imovane 7.5mg, as it has a very high potential for problematic drug misuse. Imovane 7.5mg is known to, in some case, induce a state of amnesia, which is largely related (and not too dissimilar to ’sleep-walking’). This can extend to sleep-eating, sleep-talking (quite naturally), to dangerously ’sleep driving’. It is therefore usually not used as an anti-anxiety drug (such as Benzodiazepines), as the patient may be liable to make very poor judgment decisions (as they are essentially mentally ’asleep’) and attempt dangerous activities. - With absolutely no recollection at all of the events.

Imovane 7.5mg is used to treat insomnia (inability to sleep) in adults, including difficulty in falling asleep, waking in the night or too early in the morning, severe problems of sleep due to mood or mental health problems.

Imovane 7.5mg also interacts with trimipramine and caffeine. Alcohol has an additive effect when combined with Imovane 7.5mg, enhancing the adverse effects including the overdose potential of Imovane 7.5mg significantly. A study assessing the impact of Imovane 7.5mg on driving skills the next day found that the impairments on driving skills are double that of a social dose of alcohol. Zaleplon had no detrimental effects on driving skills the next day. Carbamazepine also has additive effects when combined with Imovane 7.5mg with both drugs enhancing the side effects of each other. Erythromycin appears to increase the absorption rate of Imovane 7.5mg and prolong the elimination half life of Imovane 7.5mg leading to increased plasma levels and more pronounced effects. Itraconazole has a similar effect on Imovane 7.5mg pharmacokinetics as erythromycin. The elderly may be particularly sensitive to the erythromycin and itraconazole drug interaction with Imovane 7.5mg. Temporary dosage reduction during combined therapy may be required especially in the elderly. Rifampicin causes a very notable reduction in half life of Imovane 7.5mg and peak plasma levels which results in a large reduction in the hypnotic effect of Imovane 7.5mg. Phenytoin and carbamazepine may also provoke similar interactions. Ketoconazole and sulfaphenazole interfere with the metabolism of Imovane 7.5mg. Nefazodone impairs the metabolism of Imovane 7.5mg leading to increased Imovane 7.5mg levels and marked next day sedation.

See also:
What are the possible side effects of Imovane 7.5mg?

The side effect most commonly seen in clinical trials is taste alteration or dysgeusia (bitter, metallic taste, which is usually fleeting in most users but can persist until the drug’s half-life has expired). Palpitations may occur in the daytime following withdrawal from the drug after prolonged periods of use (especially when taken for more than two weeks).

Imovane 7.5mg induces amnesia type memory impairments similar to triazolam and Rohypnol. Impairment of driving skills with a resultant increased risk of road traffic accidents is probably the most important side effect. This side effect is not unique to Imovane 7.5mg but also occurs with other hypnotic drugs.

More common reactions

Gastrointestinal: taste disturbances including bitter metallic taste, dry mouth. Nervous system: disruption of REM sleep, double vision, drowsiness, memory impairments, visuospatial impairments, dizziness, headaches, and fatigue. Unexpected mood changes have been noted, which if experienced should lead to the drug being withdrawn from the patient.

Less common reactions

Gastrointestinal: heartburn, constipation, diarrhoea, nausea, coated tongue, bad breath, anorexia or increased appetite, vomiting, epigastric pains, dyspepsia, dehydration, parageusia.

Cardiovascular: palpitations in elderly patients.

Skin: urticaria, tingling in the arms and legs.

Miscellaneous: blurred vision, frequent micturition, mild to moderate increases in serum transaminases and/or alkaline phosphatase and interstitial nephritis have been reported very rarely.

Reproductive: impotence, delayed ejaculation, anorgasmia in both women and men.[citation needed]

Nervous system: agitation, anxiety, loss of memory including retrograde and anterograde amnesia, confusion, dizziness, weakness, somnolence, asthenia, moderate to severe euphoria and/or dysphoria, feeling of drunkenness, depression, sleep walking, coordination abnormality, hypotonia, speech disorder, hallucinations of various strengths, usually auditory and visual, behavioural disorders, aggression, tremor, rebound insomnia, nightmares, hypomania. Delirium can also occur but is a side effect mainly seen in the elderly.[26